Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
letter
. 1998 Aug;78(4):554–556. doi: 10.1038/bjc.1998.535

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.

P Cohen, D M Peehl, R Rosenfeld
PMCID: PMC2063105  PMID: 9716045

Full text

PDF
554

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bang P., Eriksson U., Sara V., Wivall I. L., Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 1991 Jun;124(6):620–629. doi: 10.1530/acta.0.1240620. [DOI] [PubMed] [Google Scholar]
  2. Daughaday W. H., Kapadia M., Mariz I. Serum somatomedin binding proteins: physiologic significance and interference in radioligand assay. J Lab Clin Med. 1987 Mar;109(3):355–363. [PubMed] [Google Scholar]
  3. Frey R. S., Hathaway M. R., Dayton W. R. Comparison of the effectiveness of various procedures for reducing or eliminating insulin-like growth factor-binding protein interference with insulin-like growth factor-I radioimmunoassays on porcine sera. J Endocrinol. 1994 Feb;140(2):229–237. doi: 10.1677/joe.0.1400229. [DOI] [PubMed] [Google Scholar]
  4. Ho P. J., Baxter R. C. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 1997 Mar;46(3):333–342. [PubMed] [Google Scholar]
  5. Kanety H., Madjar Y., Dagan Y., Levi J., Papa M. Z., Pariente C., Goldwasser B., Karasik A. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab. 1993 Jul;77(1):229–233. doi: 10.1210/jcem.77.1.7686915. [DOI] [PubMed] [Google Scholar]
  6. Laron Z., Silbergeld A. A child with phenotypic Laron dwarfism and normal somatomedin levels. N Engl J Med. 1989 Jun 22;320(25):1698–1699. doi: 10.1056/NEJM198906223202516. [DOI] [PubMed] [Google Scholar]
  7. Mantzoros C. S., Tzonou A., Signorello L. B., Stampfer M., Trichopoulos D., Adami H. O. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer. 1997;76(9):1115–1118. doi: 10.1038/bjc.1997.520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Pintor C., Loche S., Cella S. G., Müller E. E., Baumann G. A child with phenotypic Laron dwarfism and normal somatomedin levels. N Engl J Med. 1989 Feb 9;320(6):376–379. doi: 10.1056/NEJM198902093200607. [DOI] [PubMed] [Google Scholar]
  9. Pintor C., Loche S., Cella S. G., Müller E. E., Baumann G. Correction and withdrawal of conclusion--a child with phenotypic Laron dwarfism and normal somatomedin levels. N Engl J Med. 1990 Nov 22;323(21):1485–1485. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES